Hematology/Oncology · Calabasas, CA
NPI
1962405266
Since 2005
Specialty
Hematology/Oncology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
24100 Calabasas Rd Ste 100
Calabasas, CA, 91302
Phone (818) 578-6454
Groups this clinician bills Medicare through
Medicare paid, 2024
$302K
18,149 services
Medicare patients, 2024
206
Average age 75
Drug cost, 2024
$8.6M
1,922 prescriptions
Company payments, 2025
$5,907
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nader Javadi was code J1756 (injection, iron sucrose, 1 mg), 8,700 times for 16 patients. In total Nader Javadi billed 18,149 services in 52 codes, and Medicare paid $302K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-12-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 8,700 | 16 | $0.16 | $1,375 |
| 85025 Blood Count | Office | 642 | 134 | $7.61 | $4,886 |
| 36415 Venipuncture Blood Collection | Office | 553 | 127 | $8.65 | $4,783 |
| 96367 Intravenous Infusion, Hydration | Office | 479 | 37 | $25.11 | $12K |
| 99214 Office E&M - Established | Office | 478 | 146 | $103.71 | $50K |
| 96417 Chemotherapy Administration | Office | 461 | 36 | $57.47 | $26K |
| 96413 Chemotherapy Administration | Office | 421 | 52 | $115.92 | $49K |
| 96375 Injection Administration | Office | 364 | 33 | $13.65 | $4,970 |
| 96372 Injection Administration | Office | 266 | 53 | $12.12 | $3,224 |
| 81002 Clinical Chemistry | Office | 164 | 22 | $3.41 | $559 |
| 96365 Intravenous Infusion, Hydration | Office | 111 | 22 | $53.05 | $5,889 |
| 99215 Office E&M - Established | Office | 102 | 47 | $144.01 | $15K |
| 96361 Intravenous Infusion, Hydration | Office | 80 | 21 | $10.72 | $857 |
| 99205 Office E&M - New | Office | 69 | 69 | $187.48 | $13K |
| 96360 Intravenous Infusion, Hydration | Office | 62 | 17 | $26.74 | $1,658 |
By year: 2022 $507K for 177,424 services; 2023 $642K for 131,167 services; 2024 $302K for 18,149 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 642 | 134 | $7.61 | $4,886 |
| 36415 Venipuncture Blood Collection | 553 | 127 | $8.65 | $4,783 |
| 81002 Clinical Chemistry | 164 | 22 | $3.41 | $559 |
Medicare prescription drug claims, 2024
In 2024, the drug Nader Javadi prescribed most often to Medicare patients was Finasteride, with 135 prescriptions and refills. In total Nader Javadi wrote 1,922 Medicare prescriptions that cost $8.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Finasteride Generic | 135 | 172 | 31 | $595 |
| Opdivo Nivolumab | 127 | 127 | 24 | $1.5M |
| Dexamethasone Sodium Phosphate Generic | 71 | 71 | 19 | $197 |
| Avastin Bevacizumab | 69 | 69 | 17 | $528K |
| Procrit Epoetin Alfa | 64 | 64 | 17 | $258K |
| Bicalutamide Generic | 58 | 74 | 14 | $986 |
| Anastrozole Generic | 56 | 64 | Under 11 | $436 |
| Carboplatin Generic | 54 | 54 | 13 | $2,159 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 53 | 53 | 16 | $205 |
| Gemcitabine Hcl Generic | 46 | 46 | 11 | $3,141 |
| Abraxane Paclitaxel Protein-Bound | 45 | 45 | 11 | $279K |
| Famotidine Famotidine/Pf | 44 | 44 | 11 | $57.94 |
| Levothyroxine Sodium Generic | 42 | 55 | Under 11 | $219 |
| Zirabev Bevacizumab-Bvzr | 41 | 41 | Under 11 | $253K |
| Ondansetron Hcl Generic | 38 | 38 | 16 | $314 |
Brand drugs: - claims; generic drugs: 1,070 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nader Javadi $5,907 ($5,907 in general payments such as food, travel and fees) from 39 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,312.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 21 | $1,312 |
| AstraZeneca Pharmaceuticals LP AZN | 26 | $758 |
| Incyte Corporation INCY | 15 | $380 |
| E.R. Squibb & Sons, L.L.C. BMY | 13 | $285 |
| Merck Sharp & Dohme LLC MRK | 11 | $281 |
| Daiichi Sankyo Inc. 4568.T | 10 | $193 |
| Exelixis Inc. EXEL | 6 | $187 |
| Array Biopharma Inc PFE | 10 | $161 |
| Agios Pharmaceuticals, Inc. AGIO | 7 | $155 |
| Syndax Pharmaceuticals, Inc. SNDX | 11 | $155 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.